Ligand (LGND) Initiates Phase II Trial with LGD-4665 in Idiopathic Thrombocytopenic Purpura

April 24, 2008 9:41 AM EDT Send to a Friend
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that it has initiated ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login